000 04339nam a22004575i 4500
001 u372628
003 SIRSI
005 20160812084107.0
007 cr nn 008mamaa
008 101216s2011 xxu| s |||| 0|eng d
020 _a9781607619284
_9978-1-60761-928-4
040 _cMX-MeUAM
050 4 _aRC261-271
082 0 4 _a614.5999
_223
100 1 _aLokeshwar, Vinata B.
_eeditor.
245 1 0 _aBladder Tumors:
_h[recurso electrónico] :
_bMolecular Aspects and Clinical Management /
_cedited by Vinata B. Lokeshwar, Axel S. Merseburger, Stefan H. Hautmann.
264 1 _aTotowa, NJ :
_bHumana Press,
_c2011.
300 _aXVI, 468 p.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aCancer Drug Discovery and Development
520 _aClinical management of bladder cancer is challenging of the heterogeneity among bladder tumors with respect to invasion and metastasis, and frequent occurrence of new tumors in the bladder among patients treated with bladder preservation treatments. Treatment of bladder cancer spans from tumor resection and intravesical treatment, to neoadjuvant chemotherapy, radical surgery and adjuvant chemotherapy. At the same time, bladder cancer is also at the forefront of biomarker development because of the ease of developing noninvasive urine tests. The features of environment-driven carcinogenesis and divergent molecular pathways in the development of low- and high-grade tumors provide a unique opportunity for advance molecular research in cancer biology. Bladder Tumors: Molecular Aspects and Clinical Management is a collection of comprehensive reviews on the state-of-the art basic science research and clinical management of bladder cancer. The book progresses from epidemiology of bladder cancer, molecular basis of bladder carcinogenesis, to standard and molecular aspects of bladder cancer diagnosis and prognosis, and also includes various treatment aspects of both non muscle invasive and muscle invasive bladder cancer. The book features: • Epidemiology, bladder carcinogenesis and divergent molecular pathways of bladder cancer development. • Pathology of bladder tumors, cystoscopy, cytology and newer techniques of bladder cancer diagnosis. • Molecular basis, efficacy and economics of diagnostic and prognostic markers for bladder cancer, with an added feature of recent inventions of molecular nomongrams. • Clinical management of low-grade and non muscle invasive bladder tumors. • Intravesical chemotherapy versus immune (BCG) therapy. • Clinical management of patients with muscle invasive bladder cancer, including neoadjuvant therapy, various aspects of cystectomy including urinary diversion and recent advances such as laproscopic cystectomy • Adjuvant chemotherapy for metastatic bladder cancer and management of upper track tumors • Non-transitional cell carcinoma tumors. The book is truly an international effort to bring the latest development in bladder cancer to the readers. The contributing authors, leaders in their respective areas of expertise-related to bladder cancer, were assembled from different parts of the world. Since the editorial team of the book consists of a translational researcher (Vinata B. Lokeshwar) and practicing urologists with expertise in clinical research (Stefan Hautmann and Axel S. Merseburger), it the Editors’ intent to promote an ongoing dialog among researchers and urologists to help reduce morbidity, mortality associated with bladder cancer, while improving the quality of life for patients.
650 0 _aMedicine.
650 0 _aOncology.
650 0 _aToxicology.
650 1 4 _aBiomedicine.
650 2 4 _aCancer Research.
650 2 4 _aPharmacology/Toxicology.
700 1 _aMerseburger, Axel S.
_eeditor.
700 1 _aHautmann, Stefan H.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9781607619277
830 0 _aCancer Drug Discovery and Development
856 4 0 _zLibro electrónico
_uhttp://148.231.10.114:2048/login?url=http://link.springer.com/book/10.1007/978-1-60761-928-4
596 _a19
942 _cLIBRO_ELEC
999 _c200508
_d200508